Carcinoid Syndrome
Also known as: Malignant Carcinoid Syndrome / Carcinoid syndrome (disorder)
Drug | Drug Name | Drug Description |
---|---|---|
DB06791 | Lanreotide | A somatostatin analog used for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and acromegaly. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB06791 | Lanreotide | Somatostatin receptor type 2 | target |
DB06791 | Lanreotide | Somatostatin receptor type 5 | target |
DB06791 | Lanreotide | Cytochrome P450 3A4 | enzyme |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB12095 | Telotristat ethyl | 1 | Completed | 1 |
DB00104 | Octreotide | 1 / 2 | Terminated | 1 |
DB16144 | Dopastatin | 2 | Terminated | 1 |
DB13985 | Lutetium Lu 177 dotatate | 2 | Not Yet Recruiting | 1 |
DB00104 | Octreotide | 2 | Completed | 1 |
DB16277 | Paltusotine | 2 | Active Not Recruiting | 1 |
DB01269 | Panitumumab | 2 | Withdrawn | 1 |
DB15766 | Retifanlimab | 2 | Withdrawn | 1 |
DB12095 | Telotristat ethyl | 2 | Completed | 2 |
DB12095 | Telotristat ethyl | 2 | Recruiting | 1 |
DB12095 | Telotristat ethyl | 2 | Withdrawn | 2 |
DB00150 | Tryptophan | 2 | Recruiting | 1 |
DB06791 | Lanreotide | 3 | Completed | 1 |
DB12095 | Telotristat ethyl | 3 | Completed | 3 |
DB00104 | Octreotide | 4 | Terminated | 1 |
DB12095 | Telotristat ethyl | Not Available | Completed | 1 |